Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)
David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizumab vs paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer. (Abstract 4501)
Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract 9013)
Lisa A. Carey, MD, of the University of North Carolina, and Nadia Harbeck, MD, PhD, of Brustzentrum der Universität München, discuss study findings on adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Abstract 504)
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)
